Behavioural support and nicotine replacement therapy for smokeless tobacco cessation: protocol for a pilot randomised-controlled multi-country trial.
Asia
Nicotine
Smokeless
Tobacco
Tobacco use cessation
Journal
Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536
Informations de publication
Date de publication:
22 Aug 2022
22 Aug 2022
Historique:
received:
20
01
2021
accepted:
28
07
2022
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
Smokeless tobacco (ST) is consumed globally by more than 350 million people, with approximately 85% of all users based in South and Southeast Asia. In this region, ST products are cheap and easily accessible. Evidence-based interventions to people quit ST use are lacking. This study aims to test the feasibility of conducting a future definitive trial of ST cessation, using a culturally adapted behavioural intervention, and/or nicotine replacement therapy (NRT) in three South Asian countries. We will conduct a factorial design, randomised-controlled pilot trial in Bangladesh, India and Pakistan. Daily ST users will be recruited from primary health care settings in Dhaka, Noida and Karachi. Participants will be individually randomised to receive intervention A (4 or 6 mg NRT chewing gum for 8-weeks), intervention B (BISCA: face-to-face behavioural support for ST cessation), a combination of interventions A and B or usual care (Very Brief Advice - VBA). The participants will provide demographic and ST use related data at baseline, and at 6, 12 and 26 weeks of follow-up. Salivary cotinine samples will be collected at baseline and 26 weeks. The analyses will undertake an assessment of the feasibility of recruitment, randomisation, data collection and participant retention, as well as the feasibility of intervention delivery. We will also identify potential cessation outcomes to inform the main trial, understand the implementation, context and mechanisms of impact through a process evaluation and, thirdly, establish health resource use and impact on the quality of life through health economic data. The widespread and continued use of ST products in South Asia is consistent with a high rate of associated diseases and negative impact on the quality of life. The identification of feasible, effective and cost-effective interventions for ST is necessary to inform national and regional efforts to reduce ST use at the population level. The findings of this pilot trial will inform the development of larger trials for ST cessation among South Asian users, with relevance to wider regions and populations having high rates of ST use. ISRCTN identifier 65109397.
Sections du résumé
BACKGROUND
BACKGROUND
Smokeless tobacco (ST) is consumed globally by more than 350 million people, with approximately 85% of all users based in South and Southeast Asia. In this region, ST products are cheap and easily accessible. Evidence-based interventions to people quit ST use are lacking. This study aims to test the feasibility of conducting a future definitive trial of ST cessation, using a culturally adapted behavioural intervention, and/or nicotine replacement therapy (NRT) in three South Asian countries.
METHODS
METHODS
We will conduct a factorial design, randomised-controlled pilot trial in Bangladesh, India and Pakistan. Daily ST users will be recruited from primary health care settings in Dhaka, Noida and Karachi. Participants will be individually randomised to receive intervention A (4 or 6 mg NRT chewing gum for 8-weeks), intervention B (BISCA: face-to-face behavioural support for ST cessation), a combination of interventions A and B or usual care (Very Brief Advice - VBA). The participants will provide demographic and ST use related data at baseline, and at 6, 12 and 26 weeks of follow-up. Salivary cotinine samples will be collected at baseline and 26 weeks. The analyses will undertake an assessment of the feasibility of recruitment, randomisation, data collection and participant retention, as well as the feasibility of intervention delivery. We will also identify potential cessation outcomes to inform the main trial, understand the implementation, context and mechanisms of impact through a process evaluation and, thirdly, establish health resource use and impact on the quality of life through health economic data.
DISCUSSION
CONCLUSIONS
The widespread and continued use of ST products in South Asia is consistent with a high rate of associated diseases and negative impact on the quality of life. The identification of feasible, effective and cost-effective interventions for ST is necessary to inform national and regional efforts to reduce ST use at the population level. The findings of this pilot trial will inform the development of larger trials for ST cessation among South Asian users, with relevance to wider regions and populations having high rates of ST use.
TRIAL REGISTRATION
BACKGROUND
ISRCTN identifier 65109397.
Identifiants
pubmed: 35996179
doi: 10.1186/s40814-022-01146-5
pii: 10.1186/s40814-022-01146-5
pmc: PMC9396808
doi:
Types de publication
Journal Article
Langues
eng
Pagination
189Subventions
Organisme : Medical Research Council
ID : MR/P027946/2
Pays : United Kingdom
Organisme : National Institute for Health Research
ID : 17/63/76
Informations de copyright
© 2022. The Author(s).
Références
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
BMC Med Res Methodol. 2003 Nov 24;3:26
pubmed: 14633287
Addiction. 2005 Mar;100(3):299-303
pubmed: 15733243
J Glob Health. 2020 Jun;10(1):010327
pubmed: 32257149
Thorax. 2017 Feb;72(2):167-173
pubmed: 27708113
Value Health. 2014 Jan-Feb;17(1):70-6
pubmed: 24438719
J Glob Health. 2018 Dec;8(2):020101
pubmed: 30603074
Nicotine Tob Res. 2014 Jan;16(1):50-7
pubmed: 23946326
Qual Health Res. 2006 Mar;16(3):377-94
pubmed: 16449687
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Trials. 2014 Jul 22;15:296
pubmed: 25052334
BMC Public Health. 2016 Jun 10;16:501
pubmed: 27287429
Tob Control. 2013 Sep;22(5):324-30
pubmed: 22387521
J Clin Epidemiol. 2015 Nov;68(11):1375-9
pubmed: 26146089
Pilot Feasibility Stud. 2019 Feb 28;5:37
pubmed: 30858987
BMJ. 2015 Mar 19;350:h1258
pubmed: 25791983
Lancet. 2005 Jul 9-15;366(9480):172-4
pubmed: 16005342
Lancet. 2006 Aug 19;368(9536):647-58
pubmed: 16920470
Cochrane Database Syst Rev. 2015 Oct 26;(10):CD004306
pubmed: 26501380
Addiction. 2006 Jun;101(6):883-91
pubmed: 16696632
Ann Pharmacother. 1998 Oct;32(10):1067-75
pubmed: 9793600
Nicotine Tob Res. 2015 Sep;17(9):1058-66
pubmed: 25534929
Addiction. 2012 Dec;107 Suppl 2:45-52
pubmed: 23121359
Br J Addict. 1989 Jul;84(7):791-9
pubmed: 2758152
BMC Med. 2020 Aug 12;18(1):222
pubmed: 32782007
Psychopharmacology (Berl). 2006 Mar;184(3-4):637-44
pubmed: 16261317
Indian J Med Res. 2018 Dec;148(6):681-686
pubmed: 30778001
J Glob Health Rep. 2019 Aug 01;3:
pubmed: 33134559